

# **HYDROCORTISONE- hydrocortisone tablet**

## **Asclemed USA, Inc.**


-----

### **Hydrocortisone tablets, USP**

#### **DESCRIPTION**

Hydrocortisone tablets contain hydrocortisone which is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Hydrocortisone USP is white to practically white, odorless, crystalline powder with a melting point of about 215° C. It is very slightly soluble in water and in ether; sparingly soluble in acetone and in alcohol; slightly soluble in chloroform.

The chemical name for hydrocortisone is pregn-4-ene-3,20-dione,11,17,21-trihydroxy-, (11 $\beta$ )-. Its molecular weight is 362.46 and the structural formula is as outlined below.



Hydrocortisone tablets are available for oral administration in three strengths: each tablet contains either 5 mg of hydrocortisone. Inactive ingredients: calcium stearate, corn starch, lactose, mineral oil, sorbic acid, sucrose.

#### **ACTIONS**

Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems.

Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

#### **INDICATIONS AND USAGE**

Hydrocortisone tablets are indicated in the following conditions.

##### **1. Endocrine Disorders**

Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance)

Congenital adrenal hyperplasia

Non suppurative thyroiditis

Hypercalcemia associated with cancer

## **2. Rheumatic Disorders**

As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:

Psoriatic arthritis

Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)

Ankylosing spondylitis

Acute and subacute bursitis

Acute nonspecific tenosynovitis

Acute gouty arthritis

Post-traumatic osteoarthritis

Synovitis of osteoarthritis

Epicondylitis

## **3. Collagen Diseases**

During an exacerbation or as maintenance therapy in selected cases of:

Systemic lupus erythematosus

Systemic dermatomyositis (polymyositis)

Acute rheumatic carditis

## **4. Dermatologic Diseases**

Pemphigus

Bullous dermatitis herpetiformis

Severe erythema multiforme (Stevens-Johnson syndrome)

Exfoliative dermatitis

Mycosis fungoides

Severe psoriasis

Severe seborrheic dermatitis

## **5. Allergic States**

Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:

Seasonal or perennial allergic rhinitis

Serum sickness

Bronchial asthma

Contact dermatitis

Atopic dermatitis

Drug hypersensitivity reactions

## **6. Ophthalmic Diseases**

Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:

Allergic conjunctivitis

Keratitis

Allergic corneal marginal ulcers

Herpes zoster ophthalmicus

Iritis and iridocyclitis

Chorioretinitis

Anterior segment inflammation

Diffuse posterior uveitis and choroiditis

Optic neuritis

Sympathetic ophthalmia

## **7. Respiratory Diseases**

Symptomatic sarcoidosis

Loeffler's syndrome not manageable by other means

Berylliosis

Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy

Aspiration pneumonitis

## **8. Hematologic Disorders**

Idiopathic thrombocytopenic purpura in adults

Secondary thrombocytopenia in adults

Acquired (autoimmune) hemolytic anemia

Erythroblastopenia (RBC anemia)

Congenital (erythroid) hypoplastic anemia

## **9. Neoplastic Diseases**

For palliative management of:

Leukemias and lymphomas in adults

Acute leukemia of childhood

## **10. Edematous States**

To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.

## **11. Gastrointestinal Diseases**

To tide the patient over a critical period of the disease in:

Ulcerative colitis

Regional enteritis

## **12. Nervous System**

Acute exacerbations of multiple sclerosis

## **13. Miscellaneous**

Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy  
Trichinosis with neurologic or myocardial involvement

## **CONTRAINDICATIONS**

Systemic fungal infections and known hypersensitivity to components

## **WARNINGS**

In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.

Corticosteroids may mask some signs of infection, and new infections may appear during their use. Infections with any pathogen including viral, bacterial, fungal, protozoan or helminthic infections, in any location of the body, may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents that affect cellular immunity, humoral immunity, or neutrophil function. <sup>1</sup>

These infections may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. <sup>2</sup> There may be decreased resistance and inability to localize infection when corticosteroids are used.

Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.

## **Usage in pregnancy**

Since adequate human reproduction studies have not been done with corticosteroids, the use of these drugs in pregnancy, nursing mothers or women of childbearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy, should be carefully observed for signs of hypoadrenalism.

Corticosteroids have been shown to impair fertility in male rats.

Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.

Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered to patients receiving immunosuppressive doses of corticosteroids; however, the response to such vaccines may be diminished. Indicated immunization procedures may be undertaken in patients receiving nonimmunosuppressive doses of corticosteroids.

The use of hydrocortisone tablets in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen.

If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.

Persons who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids. In such children or adults who have not had these diseases, particular care should be taken to avoid exposure. How the dose, route and duration of corticosteroid administration affects the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chicken pox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chicken pox develops, treatment with antiviral agents may be considered. Similarly, corticosteroids should be used with great care in patients with known or suspected *Strongyloides* (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to *Strongyloides* hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.

## **PRECAUTIONS**

### **General Precautions**

Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstated.

There is an enhanced effect of corticosteroids on patients with hypothyroidism and in those with cirrhosis.

Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation.

The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.

Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.

Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency; hypertension; osteoporosis; and myasthenia gravis.

Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.

Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy. Discontinuation of corticosteroids may result in clinical remission.

Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that corticosteroids affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (See DOSAGE AND ADMINISTRATION.)

Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.

Pheochromocytoma crisis, which can be fatal, has been reported after administration of systemic corticosteroids. In patients with suspected pheochromocytoma, consider the risk of pheochromocytoma crisis prior to administering corticosteroids.

## **Drug Interactions**

The pharmacokinetic interactions listed below are potentially clinically important. Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. Therefore, the dose of corticosteroid should be titrated to avoid steroid toxicity. Corticosteroids may increase the clearance of chronic high dose aspirin. This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. The effect of corticosteroids on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids. Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.

## **Information for the Patient**

Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chicken pox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay.

## **ADVERSE REACTIONS**

### **Fluid and Electrolyte Disturbances**

Sodium retention  
Fluid retention  
Congestive heart failure in susceptible patients  
Potassium loss

Hypokalemic alkalosis  
Hypertension

### **Musculoskeletal**

Muscle weakness  
Steroid myopathy  
Loss of muscle mass  
Osteoporosis  
Tendon rupture, particularly of the Achilles tendon  
Vertebral compression fractures  
Aseptic necrosis of femoral and humeral heads  
Pathologic fracture of long bones

### **Gastrointestinal**

Peptic ulcer with possible perforation and hemorrhage  
Pancreatitis  
Abdominal distention  
Ulcerative esophagitis  
Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST, SGOT) and alkaline phosphatase have been observed following corticosteroid treatment. These changes are usually small, not associated with any clinical syndrome and are reversible upon discontinuation.

### **Dermatologic**

Impaired wound healing  
Thin fragile skin  
Petechiae and ecchymoses  
Facial erythema  
Increased sweating  
May suppress reactions to skin tests

### **Neurological**

Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment  
Convulsions  
Vertigo  
Headache  
Epidural lipomatosis

### **Endocrine**

Development of Cushingoid state  
Suppression of growth in children  
Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness  
Menstrual irregularities  
Decreased carbohydrate tolerance  
Manifestations of latent diabetes mellitus

Increased requirements for insulin or oral hypoglycemic agents in diabetics

### **Ophthalmic**

Central serous chorioretinopathy  
Posterior subcapsular cataracts  
Increased intraocular pressure  
Glaucoma  
Exophthalmos

### **Metabolic**

Negative nitrogen balance due to protein catabolism

### **Blood and lymphatic system disorders**

Leukocytosis

## **DOSAGE AND ADMINISTRATION**

The initial dosage of hydrocortisone tablets may vary from 20 mg to 240 mg of hydrocortisone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, hydrocortisone should be discontinued and the patient transferred to other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of hydrocortisone for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually, rather than abruptly.

### **Multiple Sclerosis**

In treatment of acute exacerbations of multiple sclerosis, daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day for 1 month have been shown to be effective (20 mg of hydrocortisone is equivalent to 5 mg of prednisolone).

## **HOW SUPPLIED**

Hydrocortisone tablets are available in the following strengths and package sizes:

**5 mg** (white, round, scored, imprinted CORTEF 5)



Bottles of 50: NDC 76420-028-50 (reabeled from NDC 59762-0073-1)

Bottles of 90: NDC 76420-028-90 (repackaged from NDC 59762-0073-1)

Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].

## **REFERENCES**

- Fekety R. Infections associated with corticosteroids and immunosuppressive therapy. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. *Infectious Diseases*. Philadelphia: WB Saunders Company 1992:1050-1.
- Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticoids. *Rev Infect Dis* 1989;11(6):954-63.

## **Repackaged and Relabeled by:**

Enovachem PHARMACEUTICALS

Torrance, CA 90501

## **PRINCIPAL DISPLAY PANEL - 5 mg Tablet Bottle Label**

Hydrocortisone Tablets, USP

5 mg

Rx only

Relabeled By:



Hydrocortisone Tablets, USP 5mg

NDC: 76420-028-50

Qty: 50

Distributed By: Greenstone LLC

Source NDC: 59762-0073-1

Description: white/round/scored;CORTEF 5

Lot #: XXXXXXXX Exp: 00/00/0000

Batch #: XXXXXXXX

Drug Status: RX



(01) 0 0376420 02850 5

(17) 000000

(10) XXXXXXXX

(21) 000000

Hydrocortisone Tablets, USP 5mg

NDC: 76420-028-50

S/N:000000

Qty: 50

Hydrocortisone Tablets, USP 5mg

NDC: 76420-028-50

S/N:000000

Qty: 50

Hydrocortisone Tablets, USP 5mg

NDC: 76420-028-50

S/N:000000

Qty: 50

CAUTION: FEDERAL LAW PROHIBITS DISPENSING WITHOUT PRESCRIPTION. SEE PACKAGE INSERT. KEEP OUT OF REACH OF CHILDREN. STORE AT 20-25C (68-77F) [SEE USP CONTROLLED ROOM TEMP].

Packaged By:



Hydrocortisone Tablets, USP 5mg

NDC: 76420-028-90

Qty: 90

Distributed By: Greenstone LLC

Source NDC: 59762-0073-1

Description: white/round/scored;CORTEF 5

Lot #: XXXXXXXX Exp: 00/00/0000

Batch #: XXXXXXXX

Drug Status: RX



(01) 0 0376420 02890 1

(17) 000000

(10) XXXXXXXX

(21) 000000

Hydrocortisone Tablets, USP 5mg

NDC: 76420-028-90

S/N:000000

Qty: 90

Hydrocortisone Tablets, USP 5mg

NDC: 76420-028-90

S/N:000000

Qty: 90

Hydrocortisone Tablets, USP 5mg

NDC: 76420-028-90

S/N:000000

Qty: 90

CAUTION: FEDERAL LAW PROHIBITS DISPENSING WITHOUT PRESCRIPTION. SEE PACKAGE INSERT. KEEP OUT OF REACH OF CHILDREN. STORE AT 20-25C (68-77F) [SEE USP CONTROLLED ROOM TEMP].

## HYDROCORTISONE

hydrocortisone tablet

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:76420-028(NDC:59762-0073)
<b>Route of Administration</b>	ORAL		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
<b>HYDROCORTISONE</b> (UNII: W4X0X7BPJ) (HYDROCORTISONE - UNII:W4X0X7BPJ)	HYDROCORTISONE	5 mg

### Inactive Ingredients

Ingredient Name	Strength
<b>CALCIUM STEARATE</b> (UNII: 776XM7047L)	
<b>STARCH, CORN</b> (UNII: O8232NY3SJ)	
<b>LACTOSE, UNSPECIFIED FORM</b> (UNII: J2B2A4N98G)	
<b>MINERAL OIL</b> (UNII: T5L8T28FGP)	
<b>SORBIC ACID</b> (UNII: X045WJ989B)	

**SUCROSE** (UNII: C151H8M554)

### Product Characteristics

<b>Color</b>	white	<b>Score</b>	2 pieces
<b>Shape</b>	ROUND (half oval)	<b>Size</b>	8mm
<b>Flavor</b>		<b>Imprint Code</b>	CORTEF;5
<b>Contains</b>			

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:76420-028-50	50 in 1 BOTTLE; Type 0: Not a Combination Product	12/24/2019	
2	NDC:76420-028-90	90 in 1 BOTTLE; Type 0: Not a Combination Product	12/24/2019	

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA authorized generic	NDA008697	02/20/2013	

**Labeler** - Asclemed USA, Inc. (059888437)

### Establishment

Name	Address	ID/FEI	Business Operations
ASCLEMED USA INC. DBA ENOVACHEM		059888437	relabel(76420-028) , repack(76420-028)

Revised: 10/2022

Asclemed USA, Inc.